Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE LACK OF RESPIRATORY EFFECTS OF THE OCULAR HYPOTENSIVE DRUG LATANOPROST IN PATIENTS WITH MODERATE-STEROID TREATED ASTHMA
Autore:
HEDNER J; SVEDMYR N; LUNDE H; MANDAHL A;
Indirizzi:
SAHLGRENS UNIV HOSP,DEPT CLIN PHARMACOL S-41345 GOTHENBURG SWEDEN PHARMACIA & UPJOHN INC UPPSALA SWEDEN
Titolo Testata:
Survey of ophthalmology
, volume: 41, anno: 1997, supplemento:, 2
pagine: 111 - 115
SICI:
0039-6257(1997)41:<111:TLOREO>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSTAGLANDINS; LUNG; BRONCHOCONSTRICTOR; PGF2-ALPHA; RECEPTOR; HEALTHY; PGD2;
Keywords:
ADRENOCEPTOR AGONIST; ASTHMA; BETA-2-ADRENERGIC AGONISTS; CORTICOSTEROIDS; GLAUCOMA; LATANOPROST;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
J. Hedner et al., "THE LACK OF RESPIRATORY EFFECTS OF THE OCULAR HYPOTENSIVE DRUG LATANOPROST IN PATIENTS WITH MODERATE-STEROID TREATED ASTHMA", Survey of ophthalmology, 41, 1997, pp. 111-115

Abstract

The use of beta blockers for glaucoma treatment may cause serious bronchoconstriction in patients with chronic obstructive pulmonary disease. The synthetic prostaglandin (PG) F2(alpha)-analogue latanoprost ,dihydro-17-phenyl-18,19,20-trinor-PGF-2-alpha-iso propylester) represents a new class of drugs for glaucoma treatment. In this study the pulmonary tolerability to latanoprost in 12 healthy volunteers and 11 (one withdrawal due to a sty before latanoprost treatment) subjects with moderate but stable steroid-treated intrinsic asthma was examined. Asthmatic subjects received 30 mu l of vehicle (placebo) at the scheduled administration times on baseline day. On a second day, a minimum of oneweek later, increasing concentrations (0.35, 115 and 350 mu g/ml) of latanoprost were added to the vehicle and given topically to both eyes. Healthy volunteers were given latanoprost only. ECG, blood pressure,heart rate, forced expiratory volume (FEV,), peak expiratory outflow (PEF) and forced vital capacity (FVC) were recorded immediately prior to and 15, 30, 45 and 60 minutes after latanoprost. Asthmatic patientsinhaled salbutamol (0.2 mg) at 60 minutes after the highest latanoprost dose. There were no significant differences in pulmonary function, blood pressure or heart rate after latanoprost in the healthy volunteers. Moreover, all parameters were unaffected in asthmatic patients on the day latanoprost was given compared to the baseline day. Latanoprost did not dampen the bronchodilator response to beta-2-adrenergic stimulation. It is concluded that latanoprost did not affect lung functionin healthy subjects or in asthmatics after a total accumulated dose 10 times that clinically recommended for glaucoma treatment. Therefore,latanoprost appears to be safe for glaucoma treatment in patients with steroid-treated stable moderate intrinsic asthma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 08:56:14